Market Performance - Chinese stock market experienced a continuous decline, with Hong Kong's consumer discretionary, materials, and telecommunications sectors leading the drop[1] - Southbound capital net purchases amounted to 22 billion RMB[1] - European stocks opened high but closed slightly up, with the UK planning to increase defense spending to 2.5% of GDP by 2027[1] Economic Indicators - Eurozone's Q4 salary growth slowed to 4.1%, indicating signs of economic slowdown[1] - U.S. consumer confidence index dropped significantly to 98.3, while inflation expectations rose to 6%[1] - Market anticipates a potential 60 basis points rate cut by the Federal Reserve this year, up from a previous expectation of 25 basis points[1] Commodity Trends - Oil prices declined due to weak U.S. consumer confidence impacting demand outlook, with expectations of OPEC+ potentially restoring production by 150,000 barrels per day in April[2] - Gold prices fell as some investors took profits at high levels[2] - Copper prices varied, with LME copper down but New York copper up due to tariff concerns on imports[2]

Investment Rating - The report maintains a "Buy" rating for CSPC Pharmaceutical, indicating a potential return of over 15% within the next 12 months [19]. Core Insights - CSPC Pharmaceutical is expected to experience a decline in net profit for the fiscal year 2024, with a forecasted decrease of 26% year-on-year to 4.35 billion RMB, primarily due to weak sales in finished drugs [1][3]. - The company anticipates that new product sales will reach 2 billion RMB in fiscal year 2024, with plans to double this figure in fiscal year 2025, driven by several innovative products [2][3]. - Despite the challenges faced in traditional drug sales, CSPC is expected to recover positive sales and net profit growth in 2025, supported by new product contributions and licensing agreements [2][3]. Financial Summary - For fiscal year 2024, CSPC's revenue is projected to decline by 7.7% to 29.04 billion RMB, while net profit is expected to drop by 27.5% [3][14]. - The company forecasts a revenue increase of 4.6% and a net profit increase of 14.7% in fiscal year 2025, with a target price maintained at 5.97 HKD [3][4]. - The financial outlook includes a projected operating profit of 6.42 billion RMB for fiscal year 2025, reflecting a recovery from the previous year's decline [3][14]. Sales Performance - Finished drug sales are expected to decline by 7% in fiscal year 2024, with significant drops in oncology and cardiovascular drug sales due to pricing pressures [1][3]. - The oncology segment is projected to see a 28% decrease in revenue, while cardiovascular drug sales are expected to decline by 15% [1][3]. Product Development - CSPC has several innovative assets in clinical trials and has successfully licensed out multiple products, which are expected to contribute positively to future revenues [2][3]. - The company is preparing to present data from its EGFR ADC Phase I clinical trial at the upcoming AACR conference, which could further enhance its product pipeline [2].

Investment Rating - The report maintains a "Buy" rating for Trip.com Group (TCOM) with a target price adjusted to $70.00, down from $71.00, reflecting a 20.4x PE for 2025E [1][4][12]. Core Insights - Trip.com reported total revenue of RMB 12.8 billion for Q4 2024, a 23% year-over-year increase, exceeding Bloomberg consensus by 4%. The non-GAAP operating profit was RMB 2.8 billion, benefiting from optimized operating expenses [1]. - For 2025, revenue is expected to grow by 20% to RMB 53.4 billion, with non-GAAP operating profit and net profit projected to increase by 23% and 38% respectively [1]. - The report indicates that while incremental investments may pressure short-term profits, they are expected to support long-term growth [3]. Summary by Sections Financial Performance - In Q4 2024, Trip.com achieved a non-GAAP operating profit margin of 21.6%, slightly above expectations, with operating expenses at 57.6% of total revenue, better than the anticipated 59.0% [3]. - The company’s revenue for FY 2024 is projected at RMB 53.4 billion, with a year-over-year growth of 19.8% [9]. Revenue Forecasts - The revenue forecast for Q1 2025 is estimated at RMB 13.8 billion, aligning with consensus expectations, driven by a 15% increase in domestic hotel bookings [2]. - The report anticipates a 60% year-over-year growth in Trip.com’s outbound tourism revenue for 2025, supported by incremental investments [2]. Valuation Metrics - The adjusted target price of $70.00 reflects a 22.2% upside from the current price of $57.30 [4]. - The report projects a non-GAAP net profit margin of 28.6% for 2025, down from previous estimates due to adjustments in outbound tourism revenue forecasts [12]. Investment Strategy - The report suggests that the recent stock price decline of 11% has already priced in concerns regarding potential profit margin compression due to increased investments for international expansion [1]. - The analysts express optimism about Trip.com’s ability to deliver positive financial results in upcoming quarters, driven by enhanced operational efficiency [1].

Investment Rating - The report maintains a "BUY" rating for Trip.com Group (TCOM) with a target price of US$70.00, reflecting a potential upside of 22.2% from the current price of US$57.30 [4][20]. Core Insights - Trip.com reported a total revenue of RMB12.8 billion for 4Q24, representing a 23% year-over-year increase, which was 4% above Bloomberg consensus estimates. The non-GAAP operating income was RMB2.8 billion, also exceeding consensus by 4% due to better-than-expected operating expenses [1]. - For 2024, Trip.com achieved a revenue growth of 20% year-over-year, totaling RMB53.4 billion, with non-GAAP operating profit and net profit growing by 23% and 38% year-over-year, respectively [1]. - The report anticipates a revenue growth of 16% year-over-year for 1Q25, aligning with consensus expectations, driven by solid booking volume growth in the domestic hotel business [2][3]. Summary by Sections Financial Performance - In 4Q24, Trip.com’s non-GAAP operating profit margin (OPM) was 21.6%, slightly better than consensus, while the gross profit margin (GPM) was 79.1%, which was below expectations [3]. - The company plans to increase investments to support long-term growth, which may lead to short-term margin pressures but is expected to enhance overall business performance in the future [3]. Revenue Forecasts - The revenue forecast for 2025 has been slightly increased by 1% to RMB61.6 billion, while the non-GAAP net profit forecast has been reduced by 1% due to anticipated slower growth in the outbound travel segment [12]. - The report estimates that Trip.com’s international business will see a revenue growth of 60% year-over-year in 2025, supported by increased investments [2]. Market Position - Trip.com’s outbound travel bookings have recovered to over 120% of 2019 levels in 4Q24, outperforming the overall market by approximately 30-40 percentage points [2]. - The company’s share price has dropped by 11% post-results, which the report suggests has already priced in concerns regarding potential margin contraction in 2025 [1].

Investment Rating - The report maintains a "BUY" rating for CSPC Pharmaceutical, indicating a potential return of over 15% over the next 12 months [17]. Core Insights - CSPC Pharmaceutical is experiencing an earnings decline primarily due to pricing pressure on its finished drug sales, with a forecasted net profit drop of 27.5% YoY for FY24 [7]. - The company anticipates a recovery in sales and net profit growth in FY25, driven by new product launches and out-licensing deals [7]. - The target price remains unchanged at HK$5.97, reflecting a potential upside of 18.8% from the current price of HK$5.03 [3]. Financial Summary - Revenue for FY22 was RMB 30,937 million, with a slight increase to RMB 31,450 million in FY23, but expected to decline to RMB 29,040 million in FY24, followed by a recovery to RMB 30,388 million in FY25 and RMB 31,300 million in FY26 [2][12]. - Net profit decreased from RMB 6,232.1 million in FY22 to RMB 6,072.7 million in FY23, with a significant drop expected to RMB 4,404.9 million in FY24, before rebounding to RMB 5,053.5 million in FY25 and RMB 5,135.5 million in FY26 [2][12]. - The earnings per share (EPS) is projected to decline from RMB 0.51 in FY22 to RMB 0.38 in FY24, with a slight recovery to RMB 0.43 in FY25 and RMB 0.44 in FY26 [2][12]. Sales Performance - Finished drug sales are projected to decrease by 7% YoY to RMB 23.84 billion in FY24, with a notable 19.3% YoY decline in Q4 FY24 [7]. - Oncology revenue is expected to decline by 28%, while cardiovascular drug sales are forecasted to fall by 15% due to pricing pressures and exclusion from VBP rounds [7]. New Product Development - CSPC aims to achieve RMB 2.0 billion in sales from new products in FY24, with plans to double this revenue in FY25, focusing on products like Mingfule and Kelingda [7]. - The company has successfully out-licensed several innovative assets and has multiple products in clinical trials, indicating a strong pipeline for future growth [7].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 168.08 RMB, representing a potential upside of 19.6% from the current price of 140.52 RMB [3][6][12]. Core Insights - The company is transitioning from a traditional equipment manufacturer to a smart imaging solution provider by deeply integrating AI applications into its product line, enhancing diagnostic support and data processing capabilities [1][6]. - The collaboration with its AI subsidiary, United Imaging Intelligence, is expected to strengthen the company's competitive edge in the medical imaging market, particularly through the "Device + AI" synergy [1][12]. - The report anticipates a recovery in performance due to ongoing medical equipment tender activities and a favorable policy environment for equipment upgrades and AI application penetration [13][12]. Financial Summary - **Sales Revenue (Million RMB)**: - FY22A: 9,238 - FY23A: 11,411 (27.4% YoY growth) - FY24E: 10,852 (-4.9% YoY decline) - FY25E: 13,194 (21.6% YoY growth) - FY26E: 16,097 (22.0% YoY growth) [2] - **Net Profit (Million RMB)**: - FY22A: 1,650.1 - FY23A: 1,977.8 (17.6% YoY growth) - FY24E: 1,573.1 (-20.5% YoY decline) - FY25E: 2,123.9 (35.0% YoY growth) - FY26E: 2,611.4 (23.0% YoY growth) [2] - **Adjusted Net Profit (Million RMB)**: - FY22A: 1,328 - FY23A: 1,665 - FY24E: 1,342 - FY25E: 1,962 - FY26E: 2,449 [2] - **Price-to-Earnings Ratio**: - FY23A: 58.6 - FY24E: 73.6 - FY25E: 54.5 - FY26E: 44.3 [2] Market Position and Shareholder Structure - The company has a market capitalization of approximately 106.26 billion RMB and a significant shareholder structure, with United Imaging Technology Group holding 20.3% and Shanghai United Investment Co., Ltd. holding 16.4% [3][4]. - The company has shown strong stock performance, with a 33.5% absolute return over six months [5]. AI Integration and Product Development - United Imaging Intelligence has developed over 100 AI medical products, with numerous certifications including 12 NMPA Class III certificates and 15 FDA approvals, indicating a strong competitive position in the AI medical imaging sector [6][7]. - The integration of AI algorithms into imaging devices enhances operational efficiency and image quality, positioning the company favorably in the market [8][11]. Future Outlook - The report projects a significant recovery in the company's performance in 2025, driven by a resurgence in medical equipment tenders and a supportive policy environment for AI applications in healthcare [13][12]. - The DCF model used in the report estimates a per-share value of 168.08 RMB, based on a WACC of 9.0% and a perpetual growth rate of 4.1% [18].

行业点评 科技行业 -工业富联2024业绩解读：2025年AI服务器需求依旧强劲 工业富联（601138 CH，未评级）2024年业绩快报显示，收入/净利润同比增长28/10%，受益于云计算和品 牌客户对AI服务器需求驱动云计算业务强劲增长，以及通用服务器市场复苏。展望2025年上半年，尽管市场担 心DeepSeek的影响会导致计算需求放缓，但我们仍然对全球人工智能基础设施投资加速以及GB200/GB300 AI服务器机架增长持正面看法，全球主要CSP 用于2025年算力投入和大模型升级的资本支出指引可作为明 证。我们相信AI服务器供应链将继续受益，包括比亚迪电子、鸿腾精密和立讯精密。 中国保险行业 - 4Q24保险资金年化财务投资收益率连续第五个季度回升 保险资金规模：2024年全行业保险资金运用余额33.26万亿元，同比+15.1%，高于行业保费收入增速 11.2%；其中，人身险公司保险资金运用余额29.95万亿元，同比+15.8% （人身险保费收入增速13.3%）， 占比90.1%；财产险公司保险资金运用余额2.2万亿元，同比+9.7%（财产险保费收入增速5.3%），占比 6.7%。 投资收益率：4Q2 ...

Market Trends - Chinese stock market experienced a pullback on February 24, with technology, healthcare, and telecommunications sectors leading the decline in Hong Kong stocks[1] - U.S. investment policies are increasing risk aversion, benefiting defensive sectors like consumer staples and utilities[1] - U.S. restrictions on investments in sensitive industries may prompt China to boost domestic demand, leading to a significant rise in the real estate sector[1] Economic Indicators - U.S. Treasury yields rose slightly, while Treasury futures prices fell, indicating a potential tightening of monetary policy despite a fragile economic recovery[1] - The Chinese yuan remained stable, with the central bank showing intentions to stabilize the currency amid rising interest rates in the money market[1] Corporate Developments - The China Securities Regulatory Commission emphasized support for leading technology firms and strategic enterprises, indicating a continued focus on financing for tech companies[1] - The return of large Chinese companies to Hong Kong is ongoing, but smaller firms face challenges due to strategic, compliance, and regulatory issues[1] European Market Insights - European stocks saw a slight decline, with the German election results providing some clarity, while French stocks dragged down the overall market[2] - Germany's proposed €200 billion defense spending plan is expected to boost defense sector stocks, despite concerns over strict fiscal rules limiting structural deficits[2] U.S. Market Performance - U.S. stock markets faced consecutive declines, particularly in information technology and consumer discretionary sectors, while healthcare and financial sectors showed some resilience[3] - The Dallas Fed's business activity index fell into contraction territory, adding to signs of economic weakness in the U.S.[3] Commodity Movements - Oil prices saw a slight increase, supported by Iraq's compensation commitments, while gold prices reached new highs due to rising risk aversion and a weaker dollar[4] - Gold prices have increased by 12% year-to-date, with significant inflows into gold ETFs marking the largest since 2022[4]

Macro Economic Overview - The report forecasts the USD/CNY exchange rate to reach 7.48, 7.33, and 7.55 by the end of 2025, 2026, and 2027 respectively, with Bloomberg's median market predictions being 7.45 and 7.35 for 2025 and 2026 [2] - The Chinese economy is expected to continue its recovery in 2025, but may slow down again in 2026, with no intention from policymakers to seek a significant depreciation of the RMB to boost exports [5] Company Analysis Bilibili (BILI US) - Bilibili reported Q4 2024 revenue of 7.73 billion RMB, a 22% year-on-year increase, and an adjusted net profit of 453 million RMB, significantly exceeding market expectations [6] - The company anticipates continued robust revenue growth in its advertising and mobile gaming segments, leading to an upward revision of FY25-FY26 earnings forecasts by 7-13% [6] NetEase (NTES US) - NetEase's Q4 2024 revenue decreased by 1.4% to 26.7 billion RMB, aligning with market expectations, while operating profit increased by 13.9% to 7.8 billion RMB [6] - The company expects new game launches to drive revenue growth in FY25, with a slight downward adjustment of total revenue forecasts by 2-3% [6] Alibaba (BABA US) - Alibaba's Q3 FY25 revenue reached 280.2 billion RMB, a 7.6% year-on-year increase, surpassing market expectations [7] - The company is optimistic about EBITA growth prospects for FY26, driven by increased adoption of its "full-site push" strategy and narrowing losses in its AIDC segment [8] Yancoal Australia (3668 HK) - Yancoal reported a net profit of 1.2 billion AUD for 2024, a 33% decline but 8% above expectations, and announced a final dividend of 0.52 AUD per share [8] - The company maintains production and cost guidance for 2025 similar to 2024, with increased capital expenditure anticipated [8] Weir Semiconductor (603501 CH) - Weir Semiconductor is positioned to benefit from the acceleration of AI applications in edge devices and the penetration of smart driving systems in vehicles [8] - The company expects revenue to grow by 27% in 2025, reaching 33 billion RMB, driven by sales growth in mobile and automotive CIS [8]